Sanner is bringing its subsidiaries under a single group identity, with Cambridge-based Springboard becoming Sanner UK as the first step in a wider integration plan.
The move follows Sanner’s acquisition of Springboard in January 2024 and brings the UK business more visibly into the group’s global medical device CDMO, pharmaceutical, biotech, and healthcare packaging operations. The company is combining early-stage innovation, human factors engineering, industrialisation, and commercial manufacturing under one brand.
Springboard has built its position around regulated medical device design and development, drawing on engineering, physics, electronics, software, and materials science. Its integration gives Sanner a stronger UK design and development base while connecting that capability to manufacturing scale, quality systems, and international customer support.
The change reflects a broader shift in regulated healthcare product development. Medical device and pharmaceutical customers increasingly want partners that can support the full route from concept to validated production, including user research, prototype development, design verification, human factors work, supplier selection, design transfer, regulatory documentation, small batch manufacturing, scale-up, and commercial production.
The handover from design to manufacturing remains one of the most difficult phases in medtech development. A device can perform well as a prototype but become difficult to assemble, test, sterilise, package, or document at scale. Bringing design and production expertise together earlier can reduce late redesign, qualification delays, and manufacturing risk.
Sanner’s wider business includes healthcare packaging, moisture management, and medical device CDMO services, creating overlap between device design, materials, storage stability, usability, and manufacturing repeatability. Drug delivery devices, diagnostic consumables, inhalers, sampling systems, and connected healthcare products all depend on that combination.
The UK medtech manufacturing base has been strengthening around regulated electronics, device development, and specialist production. ESCATEC’s ISO 13485 certification at its Lutterworth medtech electronics facility reflects the same direction, as healthcare OEMs seek partners able to combine manufacturing flexibility with documented quality management and regulatory discipline.
Medical devices are also becoming more complex. Mechanical systems, electronics, embedded software, sensors, connectivity, plastics, diagnostics, and drug delivery functions are increasingly combined in single products. Regulatory expectations around evidence, traceability, risk management, cybersecurity, and post-market surveillance continue to rise alongside that complexity.
Global supply resilience is also shaping CDMO strategy. Healthcare companies want development and manufacturing networks that can support regional requirements, manage geopolitical exposure, and provide redundancy without fragmenting quality systems. A single brand architecture can help with customer clarity, although its strength depends on whether sites operate as a connected network rather than a loose collection of acquired capabilities.
Sanner has indicated that the next step in its integration plan will involve Gilero, the US-based business it acquired in October 2024. The group has also been expanding development capability in the United States, including prototyping, assembly, and human factors engineering, pointing to a transatlantic medtech product development and manufacturing strategy.
The Cambridge operation gives Sanner a stronger platform in one of Europe’s most active medtech clusters. The region has depth in device innovation, diagnostics, drug delivery, engineering design, software, and life sciences research, but product developers still need routes into repeatable production. Linking that expertise to international manufacturing capacity gives the group a clearer offer for customers moving from early product definition to controlled scale-up.
The integration now has to preserve the technical strengths that made Springboard attractive while aligning engineering culture, quality systems, documentation, commercial processes, and customer relationships. In regulated markets, consistency is not optional. A global CDMO identity has to be backed by controlled processes and clear responsibility from design transfer through to production.
